key: cord-0874199-1zv3hure
authors: Henrina, Joshua; Santosa Putra, Iwan Cahyo; Cahyadi, Irvan; Lawrensia, Sherly; Hadi Gunawan, Hoo Felicia; Cahyadi, Alius; Franke, Jennifer; Suciadi, Leonardo Paskah
title: Clinical Characteristics and Outcomes of Venous Thromboembolism in Patients Hospitalized for COVID-19: Systematic Review and Meta-Analysis
date: 2021-02-04
journal: nan
DOI: 10.1016/j.tru.2021.100037
sha: 28131034c8a17d39f5b03dcaa9f99675e64a7778
doc_id: 874199
cord_uid: 1zv3hure

Venous thromboembolism is prevalent in hospitalized COVID-19 patients. Through systematic review and meta-analysis, we have investigated the differences in clinical characteristics and outcome of hospitalized COVID-19 patients with (+) and without (-) venous thromboembolism (VTE). 45 studies with a total of 8859 patients were included in the qualitative synthesis. Subsequently, 38 studies with a total of 7847 patients, were quantitatively analysed. There was no mortality difference between the VTE (-) and VTE (+) hospitalized COVID-19 patients (RR1.32 (0.97, 1.79); 0.07; I 2 64%, p<0.001). Patients with VTE (+) were more likely to get admitted to the intensive care unit (RR1.77 (1.26, 2.50); p<0.001; I 2 63%, p= 0.03) and mechanically ventilated (RR 2.35 (1.22, 4.53); p=0.01; I 2 88%, p<0.001). Moreover, male gender (RR 1.19 (1.14,1.24), p<0.001; I2 0%, p=0.68), increased the risk of VTE. Regarding patients lab values’, VTE (+) was significantly associated with higher white blood cell, neutrophil count, D-Dimer, alanine aminotransferase (ALT), lactate dehydrogenase (LDH), and C-reactive protein (CRP), along with prolonged prothrombin time. On the contrary, VTE (+) was associated with lower albumin and neutrophil-lymphocyte ratio (NLR). This findings provide the initial framework for risk stratification of hospitalized COVID-19 patients with VTE.

Coronavirus disease of 2019 (COVID-19) is a highly contagious respiratory disease caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) resulting in a global pandemic status. At the time of this writing, it has already claimed more than 1.6 million lives and infected approximately 70 million people throughout the world.(1) Although many aspects of this multifaceted disease have been unravled, much more are being explored. Notably, the coagulopathy associated with COVID-19, in which evidence is still emerging, has raised concerns as one of the most serious events during hospitalization with this disease. (2) (3) (4) (5) A previous study has shown that D-dimer, a primary marker of coagulopathy, was associated with higher mortality.(5) Furthermore, lung dissection and autopsy from COVID-19 decedents showed pulmonary microthrombi formation.(6) Therefore, several authors argued that Acute Respiratory Distress Syndrome (ARDS), which is the most common J o u r n a l P r e -p r o o f complication of COVID-19, is caused by pulmonary endothelial dysfunction identified as pulmonary intravascular coagulopathy (PIC) or pulmonary thrombosis. (7, 8) This argument is substantiated by several findings that the incidence of pulmonary embolism (PE) is more frequent than deep vein thrombosis (DVT). (9) Data from previous reports have shown a higher incidence of venous thromboembolism (VTE) in patients hospitalized with COVID-19 compared to with other diseases (10) , despite prophylaxis anticoagulation had been applied. (11, 12) This acute vascular complication might potentially impact morbidity and mortality of patients with COVID-19 during their hospitalization. Rapid growth of published work on this subject allows for a comprehensive analysis to reach a conclusion on this important issue.

This study aimed to systematically evaluate the impact of VTE on mortality in patients with COVID-19. Authors also scrutinized any clinical characteristics which potentially lead to developing VTE in this population during hospitalization. Thus, more attention can be given to these patients to reduce morbidity and mortality during hospitalization. To the best of our knowledge, this is the first systematic review and metaanalysis that compare hospitalized COVID-19 patients with and without VTE.

The predefined protocol was used for this review and in line with Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). We systematically searched and identified studies published between 1 January 2020 and 23 November 2020, through electronic searches using PubMed, Europe PMC, Proquest, Embase, and WHO Database.

Medical Subject Headings (MeSH) and free words were used to construct the search terms related to VTE (venous thromboembolism OR deep vein thrombosis OR pulmonary embolism), coronavirus disease of 2019 (COVID-19 OR SARS-CoV-2 OR 2019-nCoV).

Eligible articles for further review were identified by screening of titles and abstracts, followed by a full-text review. In the case of multiple publications, the most recent and complete reports were included. Authors finalized the systematic literature review search on 23 November 2020. This study adhered to the PRISMA guideline.

Articles eligibility was assessed by two independent investigators (JH and ICSP).

Discrepancies were resolved by consensus with a third investigator (AC). The inclusion J o u r n a l P r e -p r o o f criteria of the article in this study included all research studies involving hospitalized patients with COVID-19 suffering VTE (DVT group and PE group only, non-specified VTE group, and specified VTE group), which dichotomized them into two groups, ie, COVID-19 patients with and without VTE. We excluded commentaries, non-research letter, reviews, and case reports/case series.

A standardized form was used to collect the information that consists of qualitative aspects of identified studies (the first author and publication year, geographic locations, and study design), basic profiles of the patients, VTE phenotypes, and any related comorbidities. Two authors performed data extraction independently (JH and ICSP). The primary outcome was all-cause mortality. The secondary outcome was intensive care unit (ICU) admission and mechanical ventilation support. In addition, we also extracted data regarding clinical characteristics (patient characteristics, comorbidities, prophylactic anticoagulation status (received/ not), and laboratory findings). Data that was reported other than mean ± SD was transformed accordingly using a calculator (http://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html), derived from Wan et al. and Luo et al. studies.(13, 14) The risk of bias of the included studies was assessed using the Joanna Briggs Institute (JBI) clinical appraisal tool for prevalence studies by two independent authors and discrepancies were resolved via discussion. (15) Statistical analysis Review Manager 5.4 (https://training.cochrane.org/online-learning/core-software-cochranereviews/revman) was used for the meta-analysis. To characterise the association between VTE and dichotomous variables, we calculated the pooled estimates and its 95% confidence interval in the form of risk ratios (RRs) using the Mantel-Haenzel formula. Whereas, to characterise the association between VTE and continuous variables, we calculated the pooled estimates in the form of a mean difference (MD) and its standard deviation. To account for interstudy variability regardless of the heterogeneity, a random-effects model was assigned.

We used two-tailed p values with a significance set at ⩽ 0.05. To assess heterogeneity across studies, we used the inconsistency index (I 2 ) with a value above 50% or p < 0.05 indicates significant heterogeneity, whereas I 2 <25% is considered low heterogeneity. A sensitivity analysis using the leave-one-out method was set to achieve statistical robustness and detect J o u r n a l P r e -p r o o f the source of heterogeneity. Finally, an inverted funnel-plot analysis was used to qualitatively detect any publication bias.

Figure one shows the study profile. Forty-five studies with a total of 8859 patients (3, 10, were included in the qualitative synthesis. (supplementary file) Subsequently, based on a risk of bias analysis, eight studies were excluded (26, 28, 32, 40, 42, 43, 47, 49) and only 38 studies (N= 7847 patients) were included in the quantitative synthesis. (Figure 1 , Table 1 ).

Seven studies were excluded in the quantitative synthesis, correspond to the result of the risk of bias analysis. All of the extracted variables and risk of bias analysis are in the supplementary file. (Table S1 -3)

The meta-analysis with a pooled subject of 4509 patients showed that complication of VTE in patients with COVID-19 was not associated with an increased in-hospital mortality (RR1.32 (0.97, 1.79); 0.07; I 2 64%, p<0.001). Moreover, introducing subgroups consist of DVT, PE, and VTE into the analysis did not alter the significance. ( Figure 4 ) This heterogeneity can be largely explained that other studies included were PE patients, which in part, might reflect a more severe COVID-19 disease. Moreover, due to limited number of studies included, we did not perform a subgroup analysis for this association.

Clinical characteristics associated with VTE There were 51 variables that provided information on patient characteristics, preexisting comorbidities, other risk factors of VTE, and laboratory findings have been analyzed (Table 3 and Table 4 ). There were only thirteen variables associated with VTE, of which eight of them included less than ten studies.

The meta-analysis showed that the incidence of VTE in COVID-19 patients was more common in men (RR 1. 19 (1.14, 1.24), p<0.001; I2 0%, p=0.68). Moreover, the incidence of VTE was not associated with an older age. Nevertheless, the heterogeneity was considerably high (MD 0.02 (-1.57, 1.61), p =0.98; I2 64%, p<0.001). A further inspection of this variable by introducing subgroups showed that older age was not associated with either DVT, PE, or VTE.

Regarding hematology profiles, higher white blood cell (WBC) was associated with VTE (MD 1.60 (1.02, 2.18); p<0.001; I2 57%, p<0.001). This association was still significant, even after introducing subgroups consist of DVT, PE, and VTE. Likewise, higher D-Dimer levels also showed a significant association with VTE (MD 3.85 (2.62, 5.08); p<0.001; I2 95%, p<0.001), which persisted at a subgroup level. Interestingly, a prolonged prothrombin time, a marker of the extrinsic pathway of a coagulation system, was also associated with VTE in general (MD 0.67 (0.20, 1.14); p=0.005; I2 74%, p<0.001).

Nonetheless, upon further analysis by introducing a subgroup, the significance was maintained only for DVT, but not VTE.

Regarding liver enzyme, the meta-analysis revealed a significant association between Upon subgroup analysis, the significance only persisted for the PE subgroup. Additionally, higher lactate dehydrogenase (LDH) was also associated with VTE (MD 53.07 (4.64, 101.50); p=0.05; I2 81%, p<0.001). Subsequent subgroup analysis revealed that the significance was only for the VTE group and not DVT nor PE.

Other parameters, including arterial carbon dioxide partial pressure (PaCO2), the ratio between arterial oxygen partial pressure and fraction of inspired oxygen (PaO2/FiO2), and urea (Table 4 ). Nonetheless, these variables included a limited number of studies, which preclude them for subgroup analysis. Of interest, comorbidities and risk factors of VTE did not associate with COVID-19 patients that suffered VTE. ( Table 3 ) Further details of the analyses are available in supplementary file. (Table S4 - ARDS in COVID-19 is a key factor of vascular fibrin deposition due to the increased early growth response-1 (Egr-1), which triggered tissue factor transcription/translation by mononuclear phagocytes and smooth muscle cells.(65) Furthermore, there is a role of bidirectional immunothrombosis, which is heightened inflammation will shift the balance to the procoagulant state by downregulating necessary anticoagulant pathways, while upregulating tissue factor expression necessary for thrombin generation. (66) In addition, SARS-CoV-2 downregulates ACE-2 after successfully infected cells, which is a counterregulatory enzyme of Angiotensin II (AngII) that maintains the reninangiotensin system (RAS) balance in check. (67) This condition leads to a prothrombotic milieu. Interaction of AngII with angiotensin II type 1 receptor (ATR-1) will activate transcription factors, which increased adhesion and accumulation of neutrophils and macrophages to endothelial cells, and ultimately these cells will release proinflammatory cytokines and chemokines. (68, 69) All of these will preserve the vicious cycle of inflammation and coagulopathy.

SARS-CoV-2 is also known to cause direct vascular injury via ACE-2 receptors. Case series of post mortem analysis of decedents due to COVID-19 confirmed diffuse endothelial inflammation, termed endothelitis, viral elements within endothelial cells, and inflammatory cell death.(70) Furthermore, morphologic and molecular changes from autopsied decedents due to COVID-19 ARDS showed severe endothelial injury with viruses present intracellularly and disrupted cell membranes. (70) Other hallmark features were thrombosis and microangiopathy, as well as intussusceptive angiogenesis, which were 9 times and 2.7 times, respectively, more common compared to patients with influenza. (71) To the best of our knowledge, this is the first systematic review and meta-analysis that assess the differences in clinical characteristics and outcome of hospitalized COVID-19 patients with and without VTE. The meta-analysis has shown that VTE was not associated with an increased mortality compared to the non-VTE group. As this study analyzed the pooling mortality risk ratio across all VTE phenomena, bias results were probably exist indicating a potential disparity of mortality rate between PE only group and DVT only group.

Even the varied prognosis might be found among subtypes of PE including segmental, lobar, and central PEs. ( (74) Therefore, special attention is needed to screen and risk stratify for VTE in every hospitalized patients with COVID-19. (59) It is generally known that worse clinical outcomes of COVID-19 disproportionately affect the older population and male gender. However, the pathomechanisms remain elusive.

In our meta-analysis, the male gender was associated with increased risk for developing VTE.

This result might explain, in part, the rationale of worse prognosis in hospitalized males having this infection. Moreover, males also have a higher risk of first and recurrent VTE compared to woman counterparts, and it is hypothesized due to X or Y link mutation or mutation on a gene with a sex-specific effect. (75) On the contrary, our meta-analysis did not show an association between older age and VTE. This finding can be explained in part that patients of older age were at higher risk of achieving other competitive outcomes, such as in-hospital mortality, and therefore underplayed DVT and PE's true incidence in this older population. (81, 82) The association between prolonged prothrombin time (PT) and VTE incidence may be associated with extrahepatic vitamin K depletion induced by pneumonia, which is important in preventing thrombosis. (83) Our findings also showed that hihger neutrophil-lymphocyte ratio (NLR) and neutrophil count was associated with VTE incidence in COVID-19 patients. Higher NLR was associated with disease severity and mortality in COVID-19. Both findings were implicated with an increased neutrophil extracellular traps (NET) level or NETosis. (84) This molecular substance played an integral part in inflammation propagation and microvascular thrombosis. (85, 86) Surprisingly, this study did not yield any association between incidence of VTE and other comorbidities including diabetes, COPD, previous cardiovascular disease, history of VTE, smoking, and active cancer as well. Therefore, other explanations are needed to be 

Venous thromboembolism is a common complication encountered in patients with COVID-19 during hospitalization. The incidence of VTE was associated with ICU admission and mechanical ventilation. Additionally, male gender, higher levels of WBC, neutrophil count, NLR, D-Dimer, LDH, and CRP, prolonged PT, and lower albumin levels were associated with increased risks for developing VTE in this population. Further researches are needed to investigate the association between in-hospital or longer-term mortality and each subtype of 

COVID-19 coagulopathy: an evolving story

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation

Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity

Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis

Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound?

Elevated Ddimers and lack of anticoagulation predict PE in severe COVID-19 patients

Prevalence of deep venous thrombosis in ventilated COVID-19 patients: a mono-center cross-sectional study

Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan

Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease

Pulmonary embolism in COVID-19 patients: a French multicentre cohort study

Pulmonary embolism or thrombosis in ARDS COVID-19 patients: A French monocenter retrospective study

Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital

Pulmonary embolism in patients with Covid-19 pneumonia

Acute Pulmonary Embolism and COVID-19. Radiology

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Incidence of venous thromboembolism in coronavirus disease 2019: An experience from a single large academic center

Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study

Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg

Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients

Incidence of venous thromboembolism in hospitalized patients with COVID-19

DVT incidence and risk factors in critically ill patients with COVID-19

Factors Associated With Pulmonary Embolism Among Coronavirus Disease 2019 Acute Respiratory Distress Syndrome: A Multicenter Study Among 375 Patients

High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards

Higher Intensity Thromboprophylaxis Regimens and Pulmonary Embolism in Critically Ill Coronavirus Disease 2019 Patients

Venous thromboembolism in non-critically ill patients with COVID-19 infection

A higher D-dimer threshold for predicting pulmonary embolism in patients with COVID-19: a retrospective study

Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study

Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients

Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19

Computed tomography characterization and outcome evaluation of COVID-19 pneumonia complicated by venous thromboembolism

Hematological findings and complications of COVID-19

Fatal Pulmonary Thromboembolism in SARS-CoV-2-Infection

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Basic Mechanisms and Pathogenesis of Venous Thrombosis

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response

Hypoxia/Hypoxemia-Induced Activation of the Procoagulant Pathways and the Pathogenesis of Ischemia-Associated Thrombosis

Inflammation and coagulation

COVID-19, diabetes mellitus and ACE2: The conundrum

COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?

Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA

Endothelial cell infection and endotheliitis in COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)Endorsed by the

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis

Coagulopathy, and Vascular Disease in COVID-19

Hypoalbuminemia and elevated D-dimer in COVID-19 patients: a call for result harmonization

Reduced Vitamin K Status as a Potentially Modifiable Risk Factor of Severe Coronavirus Disease

Neutrophil extracellular traps in COVID-19

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications

The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities

Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy

A proposal for staging COVID-19 coagulopathy

The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience

Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19

Recommendations on testing for funnel plot asymmetry

COVID-19 and misinformation: how an infodemic fuelled the prominence of vitamin D